Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study
| Autor: | Houry S, C. Louvet, F. Maindrault-Goebel, François Paye, Brice Gayet, A. de Gramont, Olivier Rosmorduc, D. Avenin, Frédéric Selle, Laurent Hannoun, Christophe Tournigand, S. Provent, Thierry André, J. P. Lotz |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty Lung Neoplasms Neutropenia Organoplatinum Compounds Vomiting Intrahepatic bile ducts GemOx Adenocarcinoma Deoxycytidine Gastroenterology Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Progression-free survival Survival rate Aged business.industry Gallbladder Liver Neoplasms Anemia Nausea Hematology Middle Aged medicine.disease Thrombocytopenia Gemcitabine Oxaliplatin Survival Rate Biliary Tract Neoplasms Treatment Outcome medicine.anatomical_structure Oncology Biliary tract Female business Progressive disease medicine.drug |
| Zdroj: | Annals of Oncology. 15:1339-1343 |
| ISSN: | 0923-7534 |
| Popis: | Since gemcitabine-oxaliplatin (GEMOX) has been used in pancreatic adenocarcinoma, we studied its activity and tolerability in advanced biliary tract adenocarcinoma (ABTA).Consecutive adult patients with confirmed ABTA were recruited from four centers. Those in group A had performance status (PS) 0-2, bilirubin2.5x normal and received GEMOX as first-line chemotherapy. Those in group B had PS2 and/or bilirubin2.5x normal and/or prior chemotherapy. All received gemcitabine 1000 mg/m2 as a 10 mg/m2/min infusion on day 1, followed by oxaliplatin 100 mg/m2 as a 2-h infusion on day 2, every 2 weeks.Tumor sites were gallbladder (19), extrahepatic bile ducts (5), ampulla of vater (3) and intrahepatic bile ducts (29). Results for group A (n = 3) were: objective response 36% [95% confidence interval (CI) 18.7% to 52.3%], stable disease 26%, progressive disease 39%, median progression-free survival (PFS) 5.7 months and overall survival (OS) 15.4 months. Results for group B (n = 23) were: objective response 22% (95% CI 6.5% to 37.4%), stable disease 30%, progressive disease 48%, PFS 3.9 months and OS 7.6 months. National Cancer Institute Common Toxicity Criteria grade 3-4 toxicities were neutropenia 14% of patients, thrombocytopenia 9%, nausea/vomiting 5% and peripheral neuropathy 7%.The GEMOX combination is active and well tolerated in ABTA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|